WHERE MADNESS MEETS METHODS

Regulatory-compliant Agentic AI systems for HTA, HEOR, and Market Access

99.0% Sensitivity
96.0% Accuracy
95.0% Specificity

LOON LENS™ HTA-grade agentic AI HEOR and Market Access: automate SLR/ITC evidence synthesis, optimize value dossiers and forecast payer decisions to de-risk reimbursement

Our Services

Evidence Synthesis

Agentic AI systems for evidence synthesis including systematic literature reviews and meta-analyses with HTA-grade quality

Systematic Literature Reviews

HTA-grade systematic literature reviews conducted with validated AI agents achieving 99% sensitivity

Value Dossier Optimization

Prepare, assess, optimize, and continuously update HTA value dossiers to maximize drug reimbursement potential

Market Access Forecasting

AI-powered market access forecasting and payer decision simulations to de-risk drug reimbursement

AI Indirect Comparisons

AI-powered indirect treatment comparisons and feasibility assessments for regulatory submissions

Reimbursement Strategy

Streamline global HTA submissions with AI-driven insights to reduce time to market

About Loon

Loon Inc. is a regulatory-grade health systems AI company that empowers BioPharma, regulators, and clinical research organizations to fast-track and de-risk drug reimbursement, maximize value, streamline commercialization, and accelerate patient access to novel therapeutics through complex, scientifically validated, specialized agentic AI systems purpose-built for healthcare.

What is Health Technology Assessment (HTA)?

Health Technology Assessment (HTA) is the evidence-based process that national payers use to decide if new medicines, devices, or diagnostics deliver enough clinical and economic value to justify coverage. Clear HTA evidence speeds reimbursement, reduces launch risk, and shortens patient wait times.

What is HEOR?

Health Economics and Outcomes Research (HEOR) evaluates the clinical, economic, and humanistic outcomes of healthcare interventions. It's crucial for demonstrating value to payers, securing reimbursement, and ensuring timely patient access to innovative treatments.